-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On BridgeBio Pharma with Neutral Rating, Announces Price Target of $82

Benzinga·05/19/2026 14:21:31
Listen to the news
Citigroup analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral rating and announces Price Target of $82.